LAPIX Therapeutics Inc. Announces FDA Clearance of IND Application for Its Treg-Expanding Tim3/4 Agonist LPX-TI641 to Treat Multiple Sclerosis

APIX Therapeutics, Inc. announced that it has received clearance of its Investigational New Drug (IND) application from the US FDA to initiate a Phase I clinical trial for its first-in-class, immune tolerance restoration small molecule, LPX-TI641, for the treatment of multiple sclerosis.